Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP PK and Adherence in Transgender Youth
NCT03652623Phase 2Completed
- Sponsor
- Hektoen Institute for Medical Research
- Start
- Jul 2018
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Hektoen Institute for Medical Research. Primary endpoints: Change in Tenofovir Levels at Week 4, Change in Estradiol Levels at Week 4 and 1 more. Started Jul 2018; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03652623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652623.